Skip to main content
Fig. 6 | EJNMMI Research

Fig. 6

From: Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

Fig. 6

The in vivo effect of SSRIs and desipramine on [125I]MIBG levels in neuroblastoma xenografts and normal tissues. Before [125I]MIBG injection, mice received either an inhibitor (black bars) or sodium chloride (white bars; control). From left to right, the results of citalopram (20 mg/kg), fluvoxamine (50 mg/kg), sertraline (20 mg/kg), paroxetine (2 mg/kg), and desipramine (20 mg/kg) are shown. Data represent mean + SD with n = 3–6 for fluvoxamine, n = 4 for sertraline, n = 4–7 for desipramine, and n = 7–9 for citalopram. Please note the different scales of the Y-axis. Asterisks were used to indicate significance levels: *p < 0.05, **p ≤ 0.01, and ***p ≤ 0.001

Back to article page